PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
0.98%
ROE near Drug Manufacturers - Specialty & Generic median of 0.98%. Charlie Munger would verify if similar industry forces drive comparable returns.
0.68%
ROA exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.06%. Mohnish Pabrai would see if this advantage is driven by brand or cost leadership.
-0.89%
Negative ROCE while Drug Manufacturers - Specialty & Generic median is 0.24%. Seth Klarman would investigate whether a turnaround is viable.
29.74%
Gross margin 50-75% of Drug Manufacturers - Specialty & Generic median of 52.87%. Guy Spier would question if commodity-like dynamics exist.
-16.32%
Negative operating margin while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would look for a path to operational turnaround.
13.32%
Net margin exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.22%. Joel Greenblatt would see if this advantage is sustainable across cycles.